Influence of Lipid Profile and Statin Administration on Arterial Stiffness in Renal Transplant Recipients

Overview

Journal Cardiol J

Specialty Cardiology & Vascular Diseases

Date 2020 Apr 25

PMID 32329037

Citations 1

Authors

Zbigniew T Heleniak

Sarah Illersperger

Susanne Brakemeier

Alicja Debska-Slizien

Paul Bach

Klemens Budde

Fabian Halleck

Affiliations

Soon will be listed here.

Abstract

Background: Hyperlipidemia is one of the major risk factors for developing a cardiovascular disease (CVD) and it is a frequent post-transplant complication, occurring in up to 60% of the renal transplant recipients (RTRs). Lipid lowering therapy with HMG-CoA reductase inhibitors (statins) is generally recommended and may reduce the overall cardiovascular risk. The aim of this study was to evaluate the lipid profile, statin administration and their relationship with arterial stiffness parameters in RTRs.

Methods: Three hundred and forty-four stable RTRs (62.5% male) transplanted between 1994 and 2018 were randomly enrolled to the study. The following parameters of arterial stiffness was measured in each patient: ankle brachial index, carotid femoral pulse wave velocity (baPWV left and right, cfPWV) and pulse pressure (PP right and left). The study group was divided based on the use statins: 143 (41.6%) and 201 (58.4%). RTRs were qualified to the statin (+) and the statin (-) group, respectively.

Results: In the statin (+) as compared to statin (-) group there were more patients with a CVD (32.9% vs. 14.9%) and diabetes (25.2% vs. 14.4%). In the whole study group, CVD was associated with a significant increase of both baPWV and cfPWV as well as PP (8.5 mmHg). There were significant differences in arterial stiffness parameters (baPWV, cfPWV, PP) between the statin (+) and the statin (-) group.

Conclusions: Arterial stiffness was increased in RTRs with CVD and hyperlipidemia. The control of hyperlipidemia was poor in RTRs.

Citing Articles

Efficacy and safety of statin therapy in kidney transplant recipients: a systematic review and meta-analysis.

Bellos I, Lagiou P, Benetou V, Marinaki S Lipids Health Dis. 2024; 23(1):293.

PMID: 39261803 PMC: 11389595. DOI: 10.1186/s12944-024-02276-w.

References

Hjelmesaeth J, Hartmann A, Midtvedt K, Aakhus S, Stenstrom J, Morkrid L . Metabolic cardiovascular syndrome after renal transplantation. Nephrol Dial Transplant. 2001; 16(5):1047-52. DOI: 10.1093/ndt/16.5.1047. View

Waters D . LDL-cholesterol lowering and renal outcomes. Curr Opin Lipidol. 2015; 26(3):195-9. DOI: 10.1097/MOL.0000000000000176. View

Zhou M, Jaimes E, Raij L . Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension. 2004; 44(2):186-90. DOI: 10.1161/01.HYP.0000136395.06810.cf. View

DElia L, La Fata E, Iannuzzi A, Rubba P . Effect of statin therapy on pulse wave velocity: A meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2018; 40(7):601-608. DOI: 10.1080/10641963.2017.1411498. View

Holdaas H, Holme I, Schmieder R, Jardine A, Zannad F, Norby G . Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol. 2011; 22(7):1335-41. PMC: 3137581. DOI: 10.1681/ASN.2010090987. View

Pannu H, Singh D, Sandhu J . Lipid profile before and after renal transplantation--a longitudinal study. Ren Fail. 2003; 25(3):411-7. DOI: 10.1081/jdi-120021153. View

Grigoropoulou P, Tentolouris A, Eleftheriadou I, Tsilingiris D, Vlachopoulos C, Sykara M . Effect of 12-month intervention with low-dose atorvastatin on pulse wave velocity in subjects with type 2 diabetes and dyslipidaemia. Diab Vasc Dis Res. 2018; 16(1):38-46. DOI: 10.1177/1479164118805320. View

Theilade S, Claggett B, Hansen T, Skali H, Lewis E, Solomon S . Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). J Hum Hypertens. 2015; 30(1):46-52. DOI: 10.1038/jhh.2015.22. View

Kasiske B, Singer G, Watschinger B, Germain M, Bastani B . The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation. 2001; 72(2):223-7. DOI: 10.1097/00007890-200107270-00009. View

10.

Laurent S, Cockcroft J, van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D . Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006; 27(21):2588-605. DOI: 10.1093/eurheartj/ehl254. View

11.

Cravedi P, Perico N, Remuzzi G . Non-immune interventions to protect kidney allografts in the long term. Kidney Int Suppl. 2010; (119):S71-5. DOI: 10.1038/ki.2010.427. View

12.

Kasiske B . Clinical practice guidelines for managing dyslipidemias in kidney transplant patients. Am J Transplant. 2005; 5(6):1576. DOI: 10.1111/j.1600-6143.2005.00827.x. View

13.

Robertsen I, Asberg A, Granseth T, Vethe N, Akhlaghi F, Ghareeb M . More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. Transplantation. 2014; 97(12):1266-71. PMC: 4127422. DOI: 10.1097/01.TP.0000443225.66960.7e. View

14.

Holdaas H, De Fijter J, Cruzado J, Massari P, Nashan B, Kanellis J . Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy: An Analysis of the Randomized ELEVATE Study. Transplantation. 2017; 101(10):2612-2620. DOI: 10.1097/TP.0000000000001739. View

15.

Tuncer M, Suleymanlar G, Ersoy F, Yakupoglu G . Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplant Proc. 2000; 32(3):622-5. DOI: 10.1016/s0041-1345(00)00921-0. View

16.

Jardine A, Gaston R, Fellstrom B, Holdaas H . Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011; 378(9800):1419-27. DOI: 10.1016/S0140-6736(11)61334-2. View

17.

Cosio F, Pesavento T, Pelletier R, Henry M, Ferguson R, Kim S . Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis. 2002; 40(3):638-43. DOI: 10.1053/ajkd.2002.34927. View

18.

Boutouyrie P, Fliser D, Goldsmith D, Covic A, Wiecek A, Ortiz A . Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. Nephrol Dial Transplant. 2013; 29(2):232-9. DOI: 10.1093/ndt/gft309. View

19.

Mason J, Kleemann F, Bankart J, Medcalf J, Carr S . Blood pressure in renal transplant recipients: are there independent predictors for achieving target blood pressure?. Nephron Clin Pract. 2009; 111(3):c159-66. DOI: 10.1159/000198236. View

20.

Korogiannou M, Xagas E, Marinaki S, Sarafidis P, Boletis J . Arterial Stiffness in Patients With Renal Transplantation; Associations With Co-morbid Conditions, Evolution, and Prognostic Importance for Cardiovascular and Renal Outcomes. Front Cardiovasc Med. 2019; 6:67. PMC: 6543273. DOI: 10.3389/fcvm.2019.00067. View